Lack of enrollment

The purpose of this study is to compare the effectiveness of the medications acetazolamide and diazepam in the treatment of continuous spike wave in sleep (CSWS) and Landau-Kleffner syndrome (LKS).

Inclusion Criteria:

• ESES and clinical CSWS/LKS defined by all of the following:
• SWI ≥50% during first hour of sleep
• Bilateral synchrony of discharges during sleep
• Clinical evidence of behavior and/or academic regression
• Daytime SWI ≤20%

Exclusion Criteria:

• Previous treatment with benzodiazepine or acetazolamide for Electrical Status Epilepticus in Sleep (ESES)
• Current treatment with carbamazepine, phenytoin, oxcarbazepine, phenobarbital, vigabatrin or lamotrigine
• Antiepileptic medication changes over the month prior to enrollment
• Epileptic encephalopathy other than CSWS/LKS
• Prior serious adverse reaction to benzodiazepines or acetazolamide
• Sulfa allergy
• Progressive underlying neurologic condition
• Frequent seizures that would prevent the patient from maintaining a stable dose of medications
• Female patient that has begun menses or is pregnant

Adverse events will be assessed for the duration of the study for each subject, for approximately 6 months. All adverse events will be followed through to resolution or until the investigators attribute the adverse event to a cause other than the study drugs or assesses them as chronic or stable.

Study was closed due to only 3 participants recruited